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Abstract
Background: Although increased levels of plasminogen activators have been found in psoriatic lesions, the role of plasmin
converted from plasminogen by plasminogen activators in pathogenesis of psoriasis has not been investigated.
Methodology/Principal Findings: Here we examined the contribution of plasmin to amplification of inflammation in
patients with psoriasis. We found that plasminogen was diminished, but that the amount and activity of its converted
product plasmin were markedly increased in psoriasis. Moreover, annexin II, a receptor for plasmin was dramatically
increased in both dermis and epidermis in psoriasis. Plasmin at sites of inflammation was pro-inflammatory, eliciting
production of inflammatory factors, including CC chemokine ligand 20 (CCL20) and interleukin-23 (IL-23), that was mediated
by the nuclear factor-kappaB (NF-kB) signaling pathway and that had an essential role in the recruitment and activation of
pathogenic C-C chemokine receptor type 6 (CCR6)
+ T cells. Moreover, intradermal injection of plasmin or plasmin together
with recombinant monocyte/macrophage chemotactic protein-1 (MCP-1) resulted in induction of psoriasiform skin
inflammation around the injection sites with several aspects of human psoriasis in mice.
Conclusions/Significance: Plasmin converted from plasminogen by plasminogen activators plays an essential role in
amplification of psoriasiform skin inflammation in mice, and targeting plasmin receptor - annexin II - may harbor therapeutic
potential for the treatment of human psoriasis.
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Introduction
Psoriasis is a chronic skin disorder characterized by a dense
dermal infiltrate, which predominantly consists of T cells, dendritic
cells (DCs), natural killer T cells, and macrophages, and affects
approximately 0.2% to 2% of the world population [1].
Plasminogen (PLG) is mainly produced in the liver and is activated
by PLG activators, other serine proteases [2], or streptokinase (SK)
secreted by group A streptococci (GAS) [3]. PLG activators are
highly elevated in the lesional skin of psoriasis patients, suggesting
that PLG is involved in the pathogenesis of psoriasis [4,5,6].
Moreover, uninvolved skin from patients with psoriasis develops
signs of psoriatic lesions accompanied with increases in PLG
activator activity after being grafted on nude mice [7]. The role of
plasmin (PL) converted from PLG in inflammation has been
widely studied, and apart from its fibrinolytic functions, PL is a
potent cell activator [8]. However, no direct evidence for the
contribution of PL to the pathogenesis of psoriasis has been
reported.
An initial cellular event in the development of psoriatic lesions is
the infiltration of target skin by activated pathogenic T cells,
including Th17 T cells. These activated T cells produce
inflammatory mediators, such as IFN-c, IL-17 and IL-22, induce
epidermal hyperplasia and over-expression of key molecules,
which may act with keratinocytes, DCs and dermal macrophages
to sustain a cycle of inflammation leading to the psoriatic
phenotype [9,10,11,12]. In psoriasis, CCL20 produced at sites of
skin inflammation is a chemoattractant for skin-homing cutaneous
lymphocyte-associated antigen (CLA)
+CCR6
+ T cells and Th17
cells in the circulation [13,14]. A critical role for CCR6 in the
pathogenesis of psoriasis has been recently demonstrated [15]. In
addition, treating cultured human keratinocytes with IL-17 was
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CCL20, leading to the speculation that inhibition of this process
may contribute to the resolution of psoriasis [16].
Similarly, IL-23, which is a novel cytokine important for
autoimmunity, consisting of an IL-23 p19 chain and an IL-23 p40
chain, is regulated by several transcription factors including AP-1
and NF-kB [17]. IL-23 is now recognized to play an essential role
in the activation of inflammatory cells in Th1-mediated diseases
including psoriasis, where it is expressed in monocytes and
dendritic cells of lesional human skin [18]. Intradermal adminis-
tration of IL-23 into murine skin initiates a cascade of events
including erythema, mixed dermal infiltrates, and epidermal
hyperplasia via induction of the NF-kB-dependent TNF [19].
Furthermore, a recent genome-wide analysis for psoriasis suscep-
tibility loci revealed an association of psoriasis with IL-12, IL-23
and NF-kB-dependent pathways [20], stressing the potential value
of our recent approach by targeting NF-kB activation for the
treatment of psoriasis [21].
Despite the substantial progress in understanding the molecular
mechanisms underlying psoriasis, the direct evidence of the
contribution of PL to pathogenesis of psoriasis is still lacking. In
this study, we show that PLG is diminished, but that the amount
and activity of PL are markedly increased in psoriasis. The role of
PL at sites of inflammation was pro-inflammatory, eliciting
production of inflammatory factors, including CCL20 and IL-
23, that was mediated by the NF-kB signalling pathway and that
had an essential role in the recruitment and activation of
pathogenic CCR6
+ T cells. Strikingly, intradermal injection of
PL or PL together with recombinant MCP-1 resulted in induction
of psoriasiform skin inflammation around the injection sites with
several aspects of human psoriasis in mice. Thus, our findings for
the first time provide a potential mechanism for how PL converted
from PLG by PLG activators is involved in initiation and/or
worsening psoriasis by inducing the recruitment and activation of
skin-homing pathogenic T cells or by directly activating
keratinocytes in patients, suggesting that targeting PL receptor -
annexin II - may harbor therapeutic possibility for the treatment of
psoriasis.
Results
Expression of PLG is significantly diminished in psoriasis
Both PLG activators and streptococcus-derived SK contribute
to the conversion of PLG to PL [3]. Because cell-bound PLG is
more efficiently activated to PL, we first examined the expression
of PLG in PBMC from patients with psoriasis by flow cytometry
[22]. Staining with a specific mAb against human PLG
demonstrated that cell-bound PLG was significantly decreased in
PBMC from patients compared with normal individuals
(14.0764.85 vs. 5.2464.69, p=0.0002, n=12) (Figure 1A).
Immunofluorescent staining of biopsies from lesional skin of
patients with chronic plaque-type psoriasis demonstrated that PLG
was diminished in psoriatic skin (Figure 1B right). In contrast, in
normal skin derived from healthy individuals, a clear staining for
PLG was observed, particularly in the basal layer of epidermis
(Figure 1C middle, white arrows). Western blot data further
revealed decreased expression of PLG in psoriatic skin compared
to normal skin from healthy donors (Figure 1C). PLG has been
suggested to be involved in the pathology of psoriatic lesions
because lesional psoriatic epidermis has increased levels of PLG
activators, known as urokinase PA (uPA) and tissue PA (tPA),
compared to the epidermis of uninvolved skin and normal skin
[7,23]. Consistent with this report [7], we detected a very strong
staining of uPA on epidermal keratinocytes of psoriatic lesions
compared with normal controls (Figure 1D). Furthermore, in
contrast to normal skin we have found that tPA was expressed by
both epidermal keratinocytes and dermal cells in psoriatic lesions
(Figure 1E). Collectively, our data implied that intact, cell-bound
PLG was diminished in psoriasis, and this decrease may due to
increased expression of its activators, uPA and tPA.
PL activity is enhanced in psoriasis
Production of PL can be examined by measuring the circulating
plasmin-a2 antiplasmin complexes (PAP). We next measured the
total amount of PAP in plasma by ELISA. PAP levels were
significantly elevated in patients with psoriasis compared with
controls (313.71621.49 vs. 91.51626.24, p,0.0001, n=9)
(Figure 2A). Using a chromogenic assay, we assessed activity of
PL in psoriasis. We found that levels of PL activity in plasma
derived from psoriasis patients were markedly increased compared
with normal volunteers (Figure 2B), and this difference between
patients and controls is statistically significant (0.012260.0043 vs.
0.004860.0021, p=0.0034, n=9) (Figure 2C). Annexin II is a
receptor for PL, and binding of PLG to annexin II on the cell
surface markedly enhances production of PL [24]. We observed
that there was a significant increase in cell surface expression of
annexin II on PBMC derived from psoriasis patients than on
PBMC from controls (21.20611.59 vs. 10.9064.68, p=0.0251,
n=9) (Figure 2D). Furthermore, we found that CD14
+
monocytes, but not CD3
+ T cells predominantly expressed
annexin II in PBMC of patients with psoriasis (Figure 2E).
Immunofluorescent staining of biopsies from psoriatic lesions
demonstrated that annexin II was dramatically increased in both
dermis and epidermis (Figure 2F middle), whereas in normal
skin derived from controls, only a weak staining for annexin II was
found (Figure 2F right). Western blot further confirmed an
enhanced expression of annexin II in psoriatic skin compared to
normal skin from healthy donors (Figure 2G). a2-antiplasmin
contributes to the inactivation of PL activity. Strikingly, our
western blot data revealed a prominent decrease in the expression
of a2-antiplasmin in psoriatic lesions (Figure 2H). These results
constitute evidence that the activity of PL is excessive in patients
with psoriasis, and the persistence of PL activity may be favored by
increased expression of annexin II and insufficient production of
a2-antiplasmin.
PL induces psoriasiform inflammation in mouse ear skin
Previously, we have shown that administration of murine
recombinant TNF-a (rTNF-a) together with murine recombinant
MCP-1 (rMCP-1) locally induced TNF-a release and psoriasiform
skin lesions in mice [11]. To investigate whether the synergistic
actions of rMCP-1 as a recruitment factor for macrophages and
PL as a macrophage-activating protein may result in psoriasiform
skin inflammation, we simultaneously injected PL and rMCP-1 in
mouse ear skin. Indeed, 28 days after administration of PL
together with rMCP-1 in healthy ears, we were able to induce
progressive skin lesions around the injection site that were
characterized by severe erythema, scale and crust formation
(Figure 3A, white arrow). In contrast, control mice did not
show any pathological skin phenotype (Figure 3B). Histological
analysis of skin sections from mice treated with PL and rMCP-1
revealed acanthosis, hyperorthokeratosis, subcorneal microab-
scesses, dilated lymphatic vessels and a diffuse inflammatory
infiltrates in the dermis (Figure 3C), compared to normal
epidermis and dermis in the ears of control mice (Figure 3D).
Additionally, we found that injection of PL alone, but not rMCP-
1, could also induce abnormal proliferation of epidermal
keratinocytes, however with less severity of inflammation com-
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Further analysis of the ear skin of mice treated with PL and rMCP-
1 demonstrated a significant increase of acanthosis when
compared with controls (Figure 3G). Moreover, real-time RT-
PCR analysis was carried out on RNA isolated from the ears of
wild type (WT) BALB/c mice six hours post-injection of PL and
rMCP-1. We demonstrated that psoriasis-related transcripts, such
as IFN-c, TNF-a, IL-17A, CCL20, IL-23, IL-6, IL-1a and IL-22,
were significantly enhanced in mouse ears treated with PL and
rMCP-1 than those with 16PBS control (Figure 3H). Our data
suggest the proteolytic enzyme PL may have a critical role in the
progress of psoriasis.
PL-induced psoriasiform skin changes require CCR6
+ T
cells
CCR6 has been reported to be crucial in the pathogenesis of
psoriasis [15]. To identify the role of CCR6 in the development of
psoriasiform skin inflammation induced by PL, we injected PL and
rMCP-1 in the ears of CCR6 knockout (CCR62/2) mice. Six
hours after intradermal injection of PL and rMCP-1, we found no
Figure 1. Diminished PLG in psoriasis. (A) A significant reduction in the expression of PLG in PBMC of psoriasis patients was detected by flow
cytometry. (B) Cryosections from lesional skin of psoriasis patients or normal volunteers were stained with a PLG mAb (red). (C) Lysates from lesional
skin of psoriasis patients or normal skin of volunteers were subjected to western blotting for PLG expression. Human PLG was used as a positive
control (right panel). Actin - loading control. (D, E) Cryosections from lesional skin of psoriasis patients or normal volunteers were stained with uPA or
tPA mAbs (green) for its expression. Original magnification for immunofluorescent staining, 6400. e, epidermis; d, dermis. Dotted lines indicate the
border between epidermis and dermis.
doi:10.1371/journal.pone.0016483.g001
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PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16483Figure 2. Enhanced PL activity in psoriasis. (A) PL was measured by ELISA. (B) PL activity was detected by a chromogenic assay. (C) The PL
activity was represented by DA/min (absorbance/minute). (D) The percentage of annexin II
+ cells in PBMC of psoriasis patients and normal controls is
shown. (E) Expression levels of annexin II on CD14
+ monocytes and CD3
+ T cells in PBMC of psoriasis patients was measured by Flow cytometry. One
representative experiment out of 5 is shown. (F) Cryosections from lesional skin of psoriasis patients or normal volunteers were stained with an
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between CCR62/2 mice and WT mice (Figure 4A). Remark-
ably, expression levels of IL-22, IL-17A and IFN-c were
significantly decreased in CCR62/2 mice compared to WT
mice (Figure 4A). These data imply that PL can induce the
release of IL-23 and CCL20 independent of CCR6
+ T cells but
that, in contrast, the production of IL-22, IL-17A and IFN-c
requires CCR6
+ T cells. Next, we injected PL or PL and rMCP-1
or 16PBS in the ears of WT, CCR62/2 and SCID mice every
other day for a period of 28 days. Both WT and CCR62/2 ears
exhibited marked swelling starting two weeks after the initial
injection of PL or combination of PL and rMCP-1 compared
with SCID and WT control mice injected with 16PBS
(Figure 4B), indicating that PL was capable of directly inducing
keratinocyte proliferation without the infiltration of CCR6
+ T
cells in the dermis. However, our data demonstrated a less
pronounced ear thickness in WT mice injected with PL alone or
in CCR62/2 mice injected with PL and rMCP-1 when
compared to WT mice with the same treatment (Figure 4B).
H&E staining of sections from ears injected with PL or PL and
rMCP-1 showed acanthosis, dermal inflammation, and dilation of
dermal vasculature in WT mice (Figure 4C). In contrast, a
minor effect of PL and rMCP-1 injection was observed in
CCR62/2 mice, and almost no effect of PL and rMCP-1
injection was observed in SCID mice (Figure 4C). Immunoflu-
orescent staining of biopsies from ears injected with PL and
rMCP-1 revealed high infiltration of CD11b
+ macrophages in the
ear skin of both WT and CCR62/2 mice, but not in that of
SCID mice in comparison with controls (Figure 4D), suggesting
that in this experimental setting, recruitment of CD11b
+
macrophages was not blocked by the lack of CCR6. Strikingly,
we detected a remarkably decreased expression of TNF-a in
CCR62/2 ears injected with PL and rMCP-1 compared with
WT mice (Figure 4E), indicating that CCR6
+ T cells are
indispensable for the production of TNF-a and for full
development of psoriasiform skin changes.
PL triggers NF-kB-dependent IL-23 and CCL20 expression
Genes involved in regulating the NF-kB signaling pathway have
been suggested to be genetically associated with psoriasis [20]. To
investigate a potential role of NF-kB in PL-induced CCL20 and
IL-23 expression, we pretreated mouse macrophages with an
inhibitor of NF-kB (acetyl-11-keto-b-boswellic acid [AKBA])
before stimulation with PL. We extracted mRNA 6 hours after
PL (0.43 CTA U/mL) stimulation for CCL20 and IL-23, and
determined the cytokine release. Pretreatment of macrophages
with 10 mmol/mL AKBA for 30 minutes inhibited the PL-induced
CCL20 and IL-23 release in vitro, respectively (Figure 5A, B). To
further evaluate the role of NF-kB in PL-induced CCL20 and IL-
23 in vivo, we next injected PL and rMCP-1 with or without AKBA
in ears of mice. Real-time PCR was carried out 6 hours after the
treatment. Consistently, inhibition of NF-kB resulted in significant
decrease of CCL20 production (Figure 5C, E) as well as IL-23
production in vivo (Figure 5D, F). Together with our recent
finding [21], our data stressed a pivotal role of the NF-kB signaling
pathway in the PL-mediated induction of CCL20 and IL-23, and
suggest that NF-kB signaling is critical for the induction of CCL20
and IL-23 in psoriasis.
Discussion
Because increased levels of PLG activators were found in
psoriatic lesions [4,5,6,7], we performed several experiments to
examine whether PL, a major serine protease that can be
converted from PLG by PLG activators, may be directly involved
in pathogenesis of psoriasis. Our major finding is that 1)
Diminished PLG resulted in the enhanced amount and activity
of PL in psoriasis; 2) PL is a potent cell activator, and is capable of
inducing a psoriasiform skin disease that mimics human psoriasis
with acanthosis, parakeratosis, subcorneal microabscesses, and
dilated lymphatic vessels in mice.
PLG has a critical role in inflammatory responses, and this
participation is likely to depend on its interaction with specific
receptors on the cell surface [25]. In patients with psoriasis, we
detected a diminished expression of PLG and increased produc-
tion and activity of PL in PBMC or psoriatic lesions, thus
confirming an enhanced PLG activity. When the native circulating
form of PLG is bound to the cell surface, the generation of PL by
PLG activators is markedly stimulated compared to the reaction in
solution [26]. However, in agreement with previous findings
[4,5,6,7] an increase in the expression and activity of uPA and tPA
was observed in psoriatic lesions. Most importantly, we have
demonstrated for the first time that patients with psoriasis had
3.43-fold greater PL concentrations (P,0.0034) and 2.5-fold
greater PL activity (P=0.0034) than controls.
a2-antiplasmin is an important physiologic inhibitor of PL and
rapidly inactivates PL by forming a stable PL-inhibitor complex
[27]. Herein, we observed that the expression of a2-antiplasmin
was markedly decreased in psoriatic lesions compared with
controls. This may lead to a situation in which the amount of
PL generated exceeds the capacity of a2-antiplasmin to neutralize
PL and causes strong immune responses.
Annexin II is a cell-surface PLG receptor which is a calcium-
regulated, phospholipid-binding protein on endothelial cells,
macrophages, tumor cells and keratinocytes [28,29]. Consistent
withincreased PL activity, we havedetected pronounced expression
levels of annexin II on both the cell surface of PBMC and in lesional
skin from patients with psoriasis. Because production of PL was
blocked by antibodies against annexin II, over-expression of
annexin II may lead to accelerated PL production by its activators
[24]. Interestingly, S100A4 which belongs to the S100 family of
Ca2
+-binding proteins,eitheraloneorinacomplex withannexin II,
accelerates the conversion of PLG to PL [30]. However, a recent
study has demonstrated that a strong up-regulation and release of
S100A4 was observed in the upper dermis of psoriatic skin, and
blocking antibodies against S100A4 resulted in a significant
reduction of psoriatic inflammation in a human psoriasis xenograft
SCID mouse model [31]. These published data suggest that PL is
involved in pathogenesis of psoriasis.
In addition to its fibrinolytic function, PL is a potent cell
activator [8]. To directly address whether over-expression of PL is
essential for amplification of inflammation in psoriasis, we injected
PL together with or without rMCP-1 into mouse ears. We
demonstrated that injection of PL or PL and rMCP-1 resulted in
enhanced production of psoriasis-related cytokines and subsequent
ear skin inflammation with several features resembling human
psoriasis. Thus, we conclude that increased PL activity in psoriasis
contributes to disease development.
annexin II mAb (red). Original magnification, 6400. e, epidermis; d, dermis. Dotted lines indicate the border between epidermis and dermis. (G, H)
Lysates from lesional skin of psoriasis patients or normal skin of volunteers were subjected to western blotting for annexin II expression or a2-
antiplasmin expression. Actin - loading control.
doi:10.1371/journal.pone.0016483.g002
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well documented by the observation of expression of CCR6 and
CCL20 in psoriatic lesions [13] and by the finding that both IL-
17A- and IL-22-producing cells isolated from lesional skin of
patients with psoriasis displayed CCR6 [32]. We have found that
injection of PL and rMCP-1 is capable of triggering production of
CCL20 and IL-23 together with slight ear skin inflammation in
CCR62/2 mice, suggesting that macrophages, DCs or kerati-
Figure 3. Psoriasiform skin disease induced by PL in mice. The ears of WT BALB/c mice were injected intradermally every other day for 28 days
with 30 ml1 6PBS either containing 1.5 mg PL and 30 ng recombinant murine MCP-1 or alone. (A, B) Representative clinical features of ears of treated
mice. White arrow indicates severe erythema, scales and crusts. (C–F) H&E staining of ears of from mice treated with PL+rMCP-1, 16PBS, PL and
rMCP-1. k, hyperparatosis with intracorneal neutrophilic pustule; a, acanthosis; b, increased proliferative basal layer epidermal keratinocytes; d, dermal
cell infiltrate; v, dilated dermal blood vessels. Original magnification,6100. (E) Microscopic changes of ears quantified using acanthosis. (F) Real-time
RT-PCR analysis of ears with indicated treatments. * p,0.05, ** p,0.01, *** p,0.001, Student’s t test.
doi:10.1371/journal.pone.0016483.g003
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+ T cells in the development of PL-induced psoriasiform skin changes. The ears of CCR62/2 and WT
C57BL/6J mice were injected intradermally with different treatment. (A) Real-time PCR analysis of IL-23, CCL20, IL-22, IL-17A and IFN-c transcripts six
hours after injection. (B) Ear thickness of mice with indicated genotypes or treatments was measured before and at multiple time points after
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+ T cells, are the major source of
CCL20 and IL-23 under stimulation of PL in vivo. However,
production of IL-22, IL17A and IFN-c was severely decreased in
CCR62/2 ears treated with PL and rMCP-1. Furthermore, we
demonstrated that no development of skin inflammation was
observed in SCID mice treated with PL and rMCP-1. Thus, our
data clearly indicate that induction of psoriasiform skin changes by
PL requires CCR6
+ T cells.
A genome-wide scan has revealed that the NF-kB signaling
pathway has a critical role in development of psoriasis [20]. Here
we investigated whether the NF-kB signaling pathway is involved
in PL-induced pro-inflammatory gene expression in vitro and in
vivo. Using a natural NF-kB inhibitor, AKBA [21], we demon-
strated that in the presence of AKBA, the expression levels of
CCL20 and IL-23 stimulated by PL were severely decreased,
confirming that PL-induced signal transduction entails the
Figure 5. Induction of NF-kB-dependent expression of CCL20 and IL-23 by PL in vitro and in vivo. (A, B) Real-time PCR for CCL20 and IL-
23 in RNA samples prepared from macrophages with indicated treatment. Ears of WT C57BL/6J mice were injected intradermally with 1.5 mg PL and
30 ng rMCP-1, 30 ng rMCP-1, 1.5 mg PL and 30 ng rMCP-1 and 10 mol/L AKBA or 30 ml1 6PBS alone. (C, D) Six hours after injection of PL and rMCP-1,
rMCP-1 or PL alone, real-time PCR for CCL20 and IL-23 was performed. (E, F) Six hours after injection of PL and rMCP-1 or PL and rMCP-1 and AKBA,
real-time PCR for CCL20 and IL-23 was carried out. * p,0.05, ** p,0.01, *** p,0.001, Student’s t test.
doi:10.1371/journal.pone.0016483.g005
injection. (C) On day 28, ears were collected for H&E staining. Original magnification, 6100. (D, E) On day 28, cryosections from ears were stained
with CD11b (red) and TNF-a (red). Original magnification, 6100. * p,0.05, ** p,0.01, Student’s t test.
doi:10.1371/journal.pone.0016483.g004
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patients have elevated levels of PLG activators which lead to a
marked increase in the conversion of cell-bound PLG to the active
PL. The excessive amount of PL in psoriasis patients may not be
neutralized by a2-antiplasmin because this inhibitor is significantly
lower than in normal controls. Under inflammatory conditions, PL
directly binds to its cell surface receptor, annexin II, which is
expressed on activated monocytes/macrophages, DCs and
keratinocytes, a critical initiating step in the pathogenesis of
psoriasis in predisposed individuals. Activation of these inflamma-
tory cells induce pro-inflammatory gene expression, including
expression of CCL20, IL-23, TNF-a and others, which contribute
to the recruitment/activation of CCR6
+ pathogenic T cells. These
T cells produce large amounts of IFN-c, IL-17 and IL-22, leading
to the skin changes observed in human psoriasis (Figure S1).
Collectively, our findings establish PL derived from the conversion
of PLG by PLG activators in inflammatory conditions as an
essential element that may initiate and/or worsen psoriasis by
inducing the recruitment and activation of skin-homing patho-
genic T cells or by directly activating keratinocytes in patients. We
believe that targeting PL receptor - annexin II - has therapeutic
potential for the treatment of psoriasis.
Materials and Methods
Ethics statement
Mice were kept under specific pathogen-free (SPF) conditions in
compliance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals with the approval (SYXK-2003-0026)
of the Scientific Investigation Board of Shanghai Jiao Tong
University School of Medicine, Shanghai, China. To ameliorate
any suffering of mice observed throughout these experimental
studies, mice were euthanized by CO2 inhalation.
Mice
WT C57BL/6J mice, SCID mice, WT BALB/cByJ mice, and
CCR62/2 (B6.129P2-CCR6
tm1Dgen/J) mice were purchased
from the Jackson Laboratory (Bar Harbor, ME).
Clinical samples
Clinical samples were obtained following protocols approved by
Shanghai Jiao Tong University School of Medicine Review Board
and following the Declaration of Helsinki Principles. Psoriatic
lesional biopsies or PBMC from patients with moderate-to-severe
chronic plaque psoriasis were collected simultaneously (n=12).
Sex and age-matched control samples were from normal
volunteers (n=15). Patients treated with immunosuppressive
therapies were excluded.
Flow cytometry analysis
PBMCs from either patients with psoriasis or controls were
prepared as previously published [33]. The following antibodies
were used for flow cytometry, all in conjunction with AlexaFluor
555 (Caltag Laboratories): anti-human PLG (Santa Cruz), anti-
human uPA, anti-human uPA (R&D), and anti-human annexin
A2 (ABGENT). Isotype IgGs were used as controls for all
experiments.
Immunofluorescent staining
Frozen cryosections of skin from patients and volunteers or mice
with the indicated genotype or treatment were fixed in ice-cold
acetone for 10 min before staining. The following antibodies were
used for immunofluorescent staining, all in conjunction with
AlexaFluor 555 or AlexaFluor 488 (Caltag Laboratories): anti-
human PLG (Santa Cruz Biotechnology), anti-human uPA
(Abcam), anti-human tPA (Abcam), anti-human annexin A2
(Abgent), anti-mouse CD11b (Biolegend), and anti-mouse TNF-a
(Biolegend). 49,6-Diamidino-2-phenylindole (DAPI) (Fluka) was
used for the staining of nuclei. Anti-mouse IgG2b, K (BioLegend,
Cat. No.: 400302), anti-mouse IgG1, K (BioLegend, Cat. No.:
400102) and anti-Rat IgG2b, K (BioLegend, Cat. No.: 400602)
were used as control stainings.
Antibodies were diluted in antibody diluent (Dako). Immuno-
stained samples were analyzed with a fluorescence microscope
(Zeiss Axio Scope A1). Isotype IgGs were used as control stainings.
ELISA
Human total PL was measured using ELISA kits for plasmin-
alpha-2-antiplasmin (PAP) complex (Technoclone GmbH). Plasma
from patients with chronic plaque-type psoriasis and healthy
volunteers were collected and frozen immediately until analysis.
The assay was performed following the manufacturer’s protocol.
Chromozym PL activity assay
Chromozym PL (Roche) was used to measure the activity of PL.
Equivalent amounts of plasma protein (5 mg) from psoriasis
patients and controls were diluted according the manufacturer’s
protocol. Triplicates of each sample were dispensed into 96-well
plates and incubated at 37uC. After incubation, the absorbance
was read at 405 nm.
Cell culture
Purified human PL was purchased from Athens Research &
Technology. It was free of lipopolysaccharide contamination as
analyzed by the Pyrogent LAK assay (Lozna). PL activity is given
in Committee on Thrombolytic Agents (CTA) units/mL. The
murine macrophage cell line RAW264.7 was cultured in RPMI
1640 (Invitrogen, Carlsbad, CA) supplemented with 10% FCS.
Macrophages were treated with 10 mg/mL AKBA for 30 min and
subsequently stimulated with PL in lysine-free RPMI 1640 (Sigma)
for six hours before harvesting for RNA extraction.
Quantitative RT-PCR
RNA extraction and PCR were carried out as previously
described [15]. Primer sequences used were designed for murine
IFN-c (59-ATCTGGAGGAACTGGCAAAA-39,5 9-TGACGCT-
TATGTTGTTGCTG-39), TNF-a (59-GAACTGGCAGAAGA-
GGCACT-39,5 9-AGGGTCTGGGCCATAGAACT-39), IL-17A
(59-GCTCCAGAAGGCCCTCAGA-3, 59-CTTTCCCTCCGC-
ATTGACA-39, CCL20 (59-GACTGTTGCCTCTCGT-39,5 9-
TGACTCTTAGGCTGAGGA-39), IL-23 (59-CAGCAGCTC-
TCTCGGAATCT-39,5 9-TGGATACGGGGCACATTATT-
39), IL-6 (59-CACAAGTCCGGAGAGGAGAC-39,5 9-CAGAA-
TTGCCATTGCACAAC-39), IL-1a (59-GCAACGGGAAGAT-
TCTGAAG-39,5 9-TGACAAACTTCTGCCTGACG-39), IL-22
(59-GTCAACCGCACCTTTATGCT-39,5 9-GTTGAGCACC-
TGCTTCATCA-39), and b-actin (59-TGGAATCCTGTGGCA-
TCCATGAAAC-39,5 9-TAAAACGCAGCTCAGTAACAGTC-
CG-39). Cytokine and b-actin levels were calculated relative to the
amounts found in a standard sample, and murine b-actin was
employed for normalization as previously reported [15].
Western blot analysis
Lysates of psoriatic skin of patients or normal skin of healthy
individuals were prepared as previously described [21]. Anti-
human PLG (R&D, Cat. No.: MAB1939), anti-human annexin II
(AbcamH, Cat. No.:ab54771), and anti-human a2-antiplasmin
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Western blotting was performed as previously published [8].
PL-induced skin inflammation model
The ears of mice with the indicated genotypes were injected
intradermally every other day for different time periods with 30 ml
16PBS alone or containing either 1.5 mg PL and/or 30 ng
recombinant murine MCP-1 (R&D). Injected ear samples were
frozen directly in liquid nitrogen for mRNA extraction, fixed in
10% neutral buffered formalin for histology, or embedded and
frozen in OCT for immunofluorescent staining.
Statistical analysis
Quantitative data are presented as mean values 6 standard
deviation (SD). Statistical significance was determined by the two-
tailed Student’s t test or the Mann-Whitney U test in cases of a non-
Gaussian distribution. Differences were considered to be statistically
significant at values of p,0.05 *, p,0.01 **, p,0.001 ***. Statistical
analysis was performed with GraphPad Prism 5.01 software.
Supporting Information
Figure S1 A model for how plasmin is involved in
psoriasis pathogenesis. Psoriasis patients have elevated
plasminogen activators which lead to a marked increase in
conversion of cell-bound plasminogen to the active plasmin.
Insufficient production of a2-antiplasmin results in enhanced
activity of plasmin in psoriasis patients. Binding of plasmin to its
cell surface receptor annexin II activates monocytes / macro-
phages, DCs and keratinocytes, a critical initiating step in the
pathogenesis of psoriasis in predisposed individuals. Activation of
these inflammatory cells induce pro-inflammatory gene expression
including CCL20, IL-23 and TNF-a that contribute to the
recruitment / activation of CCR6
+ pathogenic T cells, which
produce large amount of IFN-c, IL-17 and IL-22, amplifying
inflammation in psoriasis. Mw, macrophages; KC, keratinocytes;
DC, dendritic cells.
(TIF)
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